5 FDA Decisions to Watch in Q1

[cafead]

via After a three-month delay due to regulatory resource constraints, tumor-infiltrating lymphocytes (TIL) leader Iovance Biotherapeutics could score the first FDA approval of a TIL therapy for advanced melanoma.

article source